Evidence map›Paper›PMID 28036384›Full record

ArticlePloS one2016

Mapping of a Mycoplasma-Neutralizing Epitope on the Mycoplasmal p37 Protein.

Min Kyu Kim, Won-Tae Kim, Hyun Min Lee, Hong Seo Choi, Yu Ra Jo, Yangsoon Lee, Jaemin Jeong, Dongho Choi, Hee Jin Chang, Dae Shick Kim and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Min Kyu KimInstitute of Anticancer Medicine Development, Department of Integrative Bioscience and Biotechnology, Sejong University, Seoul, Korea.
Won-Tae KimInstitute of Anticancer Medicine Development, Department of Integrative Bioscience and Biotechnology, Sejong University, Seoul, Korea.
Hyun Min LeeInstitute of Anticancer Medicine Development, Department of Integrative Bioscience and Biotechnology, Sejong University, Seoul, Korea.
Hong Seo ChoiInstitute of Anticancer Medicine Development, Department of Integrative Bioscience and Biotechnology, Sejong University, Seoul, Korea.
Yu Ra JoInstitute of Anticancer Medicine Development, Department of Integrative Bioscience and Biotechnology, Sejong University, Seoul, Korea.
Yangsoon LeeDepartment of Laboratory Medicine, Hanyang University College of Medicine, Seoul, Korea.
Jaemin JeongDepartment of Surgery, Hanyang University College of Medicine, Seoul, Korea.
Dongho ChoiDepartment of Surgery, Hanyang University College of Medicine, Seoul, Korea.
Hee Jin ChangCenter for Colorectal Cancer, Research Institute and Hospital of National Cancer Center, Goyang-si, Korea.
Dae Shick KimDepartment of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Young-Joo JangDepartment of Nanobiomedical Science, BK21 PLUS Global Research Center for Regenerative Medicine, Dankook University, Cheonan, Korea.
Chun Jeih RyuInstitute of Anticancer Medicine Development, Department of Integrative Bioscience and Biotechnology, Sejong University, Seoul, Korea.
Sejong University · KRHanyang University · KRDankook University · KRNational Cancer Center · KRSamsung Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many studies have shown that the mycoplasmal membrane protein p37 enhances cancer cell migration, invasion, and metastasis. Previously, we generated 6 monoclonal antibodies (MAbs) against the mycoplasmal protein p37 and showed the presence of mycoplasma-infected circulating tumor cells in the blood of hepatocellular carcinoma patients by using CA27, one of the six MAbs. When mycoplasmas were incubated with cancer cells in the presence of CA27, mycoplasma infection was completely inhibited, suggesting that CA27 is a neutralizing antibody inhibiting mycoplasma infection. To examine the neutralizing epitope of CA27, we generated a series of glutathione S-transferase (GST)-fused p37 deletion mutant proteins in which p37 was partly deleted. To express p37-coding sequences in E.coli, mycoplasmal TGA codons were substituted with TGG in the p37 deletion mutant genes. GST-fused p37 deletion mutant proteins were then screened to identify the epitope targeted by CA27. Western blots showed that CA27 bound to the residues 216-246 on the middle part of the p37 protein while it did not bind to the residues 183-219 and 216-240. Fine mapping showed that CA27 was able to bind to the residues 226-246, but its binding activity was relatively weakened as compared to that to the residues 216-246, suggesting that the residues 226-246 is essential for optimal binding activity of CA27. Interestingly, the treatment of the purified GST-tagged epitopes with urea showed that CA27 binding to the epitope was sodium dodecyl sulfate-resistant but urea-sensitive. The same 226-246 residues were also recognized by two other anti-p37 MAbs, suggesting that the epitope is immunodominant. The identification of the novel neutralizing epitope may provide new insight into the interaction between the p37 protein and host receptors.

Indexed as

A549 CellsAntibodies, MonoclonalAntibodies, NeutralizingAntigens, BacterialCarcinoma, HepatocellularCell Line, TumorEpitope MappingEpitopesGene DeletionGlutathione TransferaseHumansLiver NeoplasmsMembrane ProteinsMycoplasmaMycoplasma InfectionsRecombinant Fusion ProteinsAntibodies, MonoclonalAntibodies, NeutralizingAntigens, BacterialEpitopesGlutathione TransferaseMembrane Proteinsp37 protein, MycoplasmaRecombinant Fusion ProteinsTumor Necrosis Factor Receptor Superfamily, Member 7

Identifiers

PMID28036384
PMCPMC5201277
OpenAlexW2571203596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.